SLM124

About Slam BioTherapeutics

SLAM BioTherapeutics is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA. The company is developing a proprietary platform of anti-CD84 (SLAMF5) ADCs and bispecifics for hematologic cancers, with a lead asset, SLM124, on track for an IND filing in early 2026 and clinical trial initiation in the second half of 2026. Backed by over $10M in seed funding and led by a seasoned team with a track record of successful exits, SLAM Bio plans a $30M+ Series A round in Q3 2025 to fund initial clinical trials and pipeline expansion.

Therapeutic Areas